Alert icon

To align with industry best practices for security and data integrity, Project Data Sphere is requiring users to upgrade their browsers to one that supports encryption protocol TLS 1.2 by December 15, 2017. On that date, Project Data Sphere will disable support of browsers that permit SSL 3.0/TLS 1.0. To prevent any disruption to your access to Project Data Sphere, you must take action.
This browser was not recognized and may not be compatible with TLS 1.2 or higher. Please check with the browser's developer to confirm.
To view information about this, please visit the FAQ. If you have any further questions, please contact us.

Back to the List
Type(s) of Cancer
Breast, Gynecological
Study Phase
Phase 3
Study Completion Date
August 2013
NCT01376349Uploaded 08-21-2021
Access via NCI by Request
PDS UID: nci-data-483
Vaginal DHEA for Vaginal Symptoms: A Phase III Randomized, Double Blind, Placebo- Controlled Trial
Provider Information
Provider Data DescriptionDataset NCT01376349-D1-Dataset.csv (consort) is one of 6 datasets associated with PubMed ID 28921241. This dataset contains information regarding whether patients were included in the primary analysis. At the time of publication, 353 (Placebo=118; DHEA 3.25 mg=123; DHEA 6.5 mg=112) patients were used in the primary analysis. The updated data in NCT01376349-D1-Dataset includes a variable ?endpoint? which identifies which patients are currently evaluable for the primary endpoint based on updated data. This includes 344 (Placebo=108; DHEA 3.25 mg=123; DHEA 6.5 mg=113).
SponsorAlliance for Clinical Trials in Oncology
Data ProviderNational Cancer Institute
Clinical Trials.gov Information
Brief SummaryRATIONALE: Dehydroepiandrosterone (DHEA) may help relieve vaginal symptoms in female cancer survivors. PURPOSE: This randomized phase III trial studies DHEA to see how well it works compared to placebo in treating postmenopausal cancer survivors with vaginal symptoms.
ConditionsBreast Cancer
Gynecologic Cancer
Intervention TypeDrug: prasterone
Other: placebo
Drug(s)Drug: prasterone
Total Enrolled464
RandomizationRandomized
Blinding MethodDouble
Arms InterventionArm I low dose DHEA - Experimental
Arm II high dose DHEA - Experimental
Arm III placebo - Placebo Comparator
Secondary IDNCCTG-N10C1
PubMed (PMID)N/A
Collaborator(s)National Cancer Institute (NCI)
Mayo Clinic
Region(s)United States
Age Range18 Years and older (Adult, Older Adult)
Files: NCT01376349-D1
Data DictionaryNCT01376349-D1-Data-Dictionary_3.pdf
DATANCT01376349-D1-Dataset_3.csv
OTHERREADME.pdf
Files: NCT01376349-D2
Data DictionaryNCT01376349-D2-Data-Dictionary_3.pdf
DATANCT01376349-D2-Dataset_2.csv
OTHERREADME.pdf
Files: NCT01376349-D3
Data DictionaryNCT01376349-D3-Data-Dictionary_3.pdf
DATANCT01376349-D3-Dataset_2.csv
OTHERREADME.pdf
Files: NCT01376349-D4
Data DictionaryNCT01376349-D4-Data-Dictionary_3.pdf
DATANCT01376349-D4-Dataset_2.csv
OTHERREADME.pdf
Files: NCT01376349-D5
Data DictionaryNCT01376349-D5-Data-Dictionary_3.pdf
DATANCT01376349-D5-Dataset_2.csv
OTHERREADME.pdf
Files: NCT01376349-D6
Data DictionaryNCT01376349-D6-Data-Dictionary_2.pdf
DATANCT01376349-D6-Dataset_3.csv
OTHERREADME.pdf
© 2023 Project Data Sphere
All rights reserved
Privacy PolicyTerms of Use